Phenotyping Patients With Type 2 Diabetes Mellitus and Cancer
Launched by AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITA · Mar 1, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into the relationship between type 2 diabetes and cancer. Researchers want to understand how certain risk factors in people with type 2 diabetes might lead to the development of cancer. They believe that conditions like obesity and high blood sugar can create an environment in the body that might promote cancer growth. By identifying these risk factors, the study aims to help improve preventive strategies and clinical practices for patients with both diabetes and cancer.
To participate in this trial, individuals must be of legal age and have been diagnosed with type 2 diabetes. However, those who had cancer before being diagnosed with diabetes or have diabetes due to other health issues or surgeries are not eligible. Participants can expect to provide information about their health and treatment history, which will help researchers gather important data. The trial is currently recruiting participants and is open to people of all genders, aged 65 and older.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Legal age
- • Diagnosis of type 2 diabetes mellitus
- Exclusion Criteria:
- • Diagnosis of cancer before diagnosis of type 2 diabetes
- • Diagnosis of diabetes secondary to other diseases
- • Diagnosis of diabetes secondary to other drugs
- • Diagnosis of diabetes following surgery
About Azienda Ospedaliero Universitaria Maggiore Della Carita
Azienda Ospedaliero Universitaria Maggiore della Carità is a leading academic hospital in Italy, renowned for its commitment to advancing healthcare through innovative clinical research and comprehensive patient care. With a focus on a wide range of medical specialties, the institution collaborates with various research entities to conduct rigorous clinical trials aimed at improving treatment outcomes and enhancing medical knowledge. Its state-of-the-art facilities and multidisciplinary approach ensure high-quality standards in research, fostering an environment conducive to scientific discovery and the development of new therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Novara, , Italy
Patients applied
Trial Officials
Flavia Prodam, MD PhD
Principal Investigator
AOU Maggiore della Carità di Novara
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported